eOnOff - D1 Extension
Completed
Conditions studied: Parkinson Disease
In brief
Clinical assessments can only offer a snapshot of daily life with Parkinson's Disease, while wearable devices can offer immensely more information that can improve the understanding of this disease. With recent advancements in technology, investigators are now able to use watch-like devices to more effectively measure the symptoms of Parkinson's Disease outside of the doctor's office. The present study is designed to evaluate the usability, applicability, and interpretability of an electronic VA Patient Motor Diary (eON-OFF), MC10 BioStampRC actigraphy sensor, APDM actigraphy sensor and the GENEActiv Watch in persons with Parkinson's Disease. There is no placebo/control group.
Key facts
- Study ID
- NCT03247387
- Run by
- Boston University
- People needed
- 34
- Starts
- 2017-05-02
- Expected to finish
- 2019-01-22
- Last updated by the study team
- 2019-01-24
Who can join
Age: 45 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Self-reported clinical diagnosis of Parkinson's disease consistent with the United Kingdom (UK) Parkinson's Disease Society Brain Bank Clinical Diagnostic Criteria.
- Self-reported ability to recognize their "wearing off" symptoms and confirmation that they usually improve after their next dose of Parkinson's disease medication.
- Parkinson's disease Hoehn \& Yahr Stage less than or equal to III (assessed while the patient is "ON").
- Currently responding to L-Dopa therapy. On a stable dose of L-Dopa (or L-Dopa equivalent) of at least 300 mg total daily dose for at least 28 days prior to Day 1, in conjunction with a dopa decarboxylase inhibitor (e.g., L-Dopa/carbidopa or L-Dopa/benserazide) divided in at least 3 divided doses per day.
- 45-75 years old
- Able to understand and cooperate with study procedures and give informed consent.
- Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study
- Body Mass Index (BMI) of 17.5 to 35 kg/m2; and a total body weight of greater than or equal to 45kg.
- Native English speaker or demonstrated fluency in English.
- Normal or corrected-to-normal vision
- A score of greater than or equal to 26 on the Mini Mental State Examination (MMSE).
- A score of 49 on the Green Form of the WRAT-4 Word Reading Subtest (equivalent to 8th grade reading level)
You may not qualify if…
- Treatment with an investigational drug within 30 days of Day 1 of study activities.
- Diagnosis of moderate to severe alcohol use disorder within 6 months of the screening as disclosed by the subject
- Employees, student, or advisee of the Principal Investigator
- History of head injury with clinically significant sequelae (e.g. loss of consciousness for greater than 15 minutes).
- DSM-V diagnosis of current, or history of, neurological disease (except for Parkinson's disease), Schizophrenia Spectrum or Other Psychotic disorders, or Bipolar and Related Disorders as disclosed by the subject.
- Subjects with cardiac pacemakers, electronic pumps, or any other implanted medical devices, including deep brain stimulation devices.
- Women of childbearing age will be required to undergo a pregnancy test to rule out a possible pregnancy.
- Allergy to adhesives or silicone
Where it is running
- Evans Biomedical Research Center — Boston, Massachusetts, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.